Therapeutic retroviral vectors for gene therapy

Patent metadata

Field	Value
Publication number	US-10105451-B2
Application number	US-201514700021-A
Country	US
Kind code	B2
Filing date	Apr 29, 2015
Priority date	Dec 13, 2002
Publication date	Oct 23, 2018
Grant date	Oct 23, 2018

Abstract

The invention provides improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. The invention further provides improved gene therapy methods for treating hematopoietic-related disorders. Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.

First claim

What is claimed is:

1. A method of treating a human subject that has sickle cell disease (SCD) or β-thalassemia comprising:
a) transducing human hematopoietic stem cells from the human subject with a self-inactivating (SIN) human immunodeficiency virus type 1 (HIV-1) lentiviral vector, wherein the lentiviral vector comprises,
a modified 5′ long terminal repeat (LTR), wherein the promoter of the modified 5′ LTR is replaced with a heterologous promoter;
an RNA export element;
a lentiviral central polypurine tract or DNA FLAP (cPPT/FLAP) sequence;
a β-globin promoter;
a β-globin locus control region (LCR), wherein the β-globin promoter and β-globin LCR are operatively linked to a nucleic acid encoding a human β-globin, a human β A-T87Q -globin or a human γ-globin; and
a modified 3′ LTR, wherein the modified 3′ LTR comprises at least one deletion compared to the wild-type 3′ LTR; and

b) intravenously administering the transduced human hematopoietic stem cells to the human subject.

2. The method of claim 1 , wherein the SIN lentiviral vector comprises a modified 5′ LTR further comprises a deletion compared to the wild-type 5′ LTR.

3. The method of claim 1 , wherein the heterologous promoter of the SIN lentiviral vector is a cytomelagovirus (CMV) promoter.

4. The method of claim 1 , wherein the RNA export element of the SIN lentiviral vector comprises a hepatitis B virus post-transcriptional regulatory element (PRE) or a human immunodeficiency virus (HIV) rev response element (RRE).

5. The method of claim 1 , wherein the modified 3′ LTR of the SIN lentiviral vector comprises a polyadenylation sequence.

6. The method of claim 1 , wherein the β-globin LCR of the SIN lentiviral vector comprises DNase I hypersensitive sites 2, 3, and 4 from the human β-globin LCR.

7. The method of claim 1 , wherein the SIN lentiviral vector comprises a human β-globin 3′ enhancer element.

8. The method of claim 1 , wherein the SIN lentiviral vector does not comprise an insulator element.

9. The method of claim 1 , wherein the SIN lentiviral vector comprises a nucleic acid cassette comprising a suicide gene operably linked to a promoter or a gene for in vivo selection of the cell.

10. The method of claim 9 , wherein the suicide gene of the SIN lentiviral vector is herpes simplex virus thymidine kinase (HSV-Tk).

11. The method of claim 9 , wherein the gene for in vivo selection of the SIN lentiviral vector is methylguanine methyltransferase (MGMT).

Assignees

• Bluebird Bio Inc
• Massachusetts Inst Technology

Inventors

• Leboulch Philippe Louis
• Pawliuk Robert
• Westerman Karen

Classifications

• C12N2740/16043

  viral genome or elements thereof as genetic vector · CPC title

• C12N2830/40

  being an insulator · CPC title

• A61P7/06

  Antianaemics · CPC title

• C12N15/867

  Retroviral vectors · CPC title

• C12N15/86

  Viral vectors · CPC title